Investors of GeneDx Holdings Corp. Urged to Join Class Action for Securities Fraud Allegations

Hagens Berman Alerts Investors in GeneDx Holdings Corp.

In a significant development for shareholders of GeneDx Holdings Corp. (NASDAQ: WGS), the law firm Hagens Berman Sobol Shapiro LLP has announced the filing of a securities fraud class-action lawsuit against the company. The lawsuit is primarily aimed at protecting the interests of investors who may have suffered substantial losses as a result of alleged misrepresentations made by the company’s management. Currently, investors are urged to contact the firm to take part in this legal action, especially as the deadline for potential lead plaintiffs approaches on August 3, 2026.

Key Details of the Case

The lawsuit covers a class period from April 16, 2025, to May 4, 2026. During this time, the firm alleges that GeneDx, along with several top executives, made materially false and misleading statements about the company’s financial health and the benefits of its acquisition of Fabric Genomics. Among the primary allegations are claims that the executives promoted Fabric as a cutting-edge, AI-driven growth catalyst, which would supposedly facilitate recurring revenue streams and efficiency gains. However, the reality appears to be much different, with claims that executives were aware of significant integration challenges that could jeopardize the company's overall performance.

Allegations of Concealment

The allegations suggest that GeneDx misled investors by painting a rosy picture of its operational capabilities, all the while concealing the internal difficulties it faced in integrating Fabric Genomics into its operations. These challenges reportedly included issues with operational compatibility and market pressures, which were not disclosed to shareholders prior to significant drops in company value.

Impact of Disclosures

The artificial inflation of GeneDx's stock price came crashing down on May 4, 2026, when the company released its first-quarter earnings, which were far below market expectations. The announcements included disappointing revenue results for both its genome and exome testing lines, with adjusted gross margins dropping significantly from 74% to 69%.

Additionally, the company slashed its full-year revenue guidance, forecasting earnings between $475 million and $490 million. This marked a sharp decline from earlier estimates of $540 million to $550 million. Perhaps most alarming was the revelation of an impairment charge amounting to $31.2 million, directly tied to the acquisition of Fabric Genomics. This charge erased nearly 94% of the funds invested in this acquisition just a year prior.

Investor Reaction

The market responded to these disclosures with disbelief, causing GeneDx shares to plummet by 49.2% in just one trading day. The stock fell dramatically from $67.93 to $34.51 per share, amounting to a monumental loss in market capitalization and obliterating billions of dollars in shareholder value. The fallout evidenced how serious the alleged mismanagement was and how far-reaching its consequences could be for everyday investors who trusted the company’s leadership.

What Affected Investors Should Do

For any investors who acquired GeneDx common stock during the class period and experienced significant losses, the lead plaintiff application deadline is fast approaching on August 3, 2026. Individuals are encouraged to reach out to Hagens Berman to discuss their potential claims or to look into the possibility of being appointed as lead plaintiffs for this class action.

Hagens Berman is particularly interested in speaking to any investors who believe they may have specialized knowledge relevant to the investigation. Additionally, whistleblowers with non-public information related to GeneDx are encouraged to come forward, as the law firm is also exploring options for those individuals through the SEC Whistleblower Program, which may offer rewards up to 30% based on successful recovery outcomes.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a leading litigation firm focused on corporate accountability and protecting the rights of investors. With a strong record of securing more than $2.9 billion for clients, the firm is well equipped to handle complex securities fraud cases like this one and serves as a strong ally for investors seeking to protect their financial interests. More information can be found at hbsslaw.com.

For additional inquiries, individuals can contact Hagens Berman directly at 844-916-0895 or via email at [email protected]